Table 5.
Delivery System/Method Employed | Polymer Used | Drugs/API | Structure | Details | References |
---|---|---|---|---|---|
PAMAM Dendrimer |
Amine and ester-terminated PAMAM Dendrimers | Nifedipine | Dendrimers composed of poly (amidoamine), or PAMAM, can improve the solubility of insoluble drugs in water at pH 7. | [163] | |
Dendrimers made of polyamidoamine(PAMAM) G3.5 and PAMAM G4.5. | Oxaliplatin | The solubility of oxaliplatin increases roughly linearly with dendrimer concentration. | [164] | ||
Dendrimers made from PAMAM | Temozolomid | TMZ solubility was shown to be enhanced in some solvent systems, with dendrimer, ethanol, and tween-20 showed construction and related in solubility. | [165] | ||
PAMAM dendrimers with pyrrolidone modification | Indomethacin | The drug’s solubility and intracellular delivery are being improved | [166] | ||
PAMAM dendrimers | Nicotinic acid | PAMAM dendrimers of different generations (G1–G4) have the ability to dramatically improve nicotinic acid solubility. | [167] | ||
Polyether dendrimer | Artemether | Due to their excellent water solubility, non-immunogenicity, and increased biocompatibility, they are used as drug carriers. | [168] | ||
PAMAM dendrimers | Ibuprofen | PAMAM dendrimers improve ibuprofen solubility much more than SDS micelles. | [169] | ||
PAMAM and Lauryl PAMAM dendrimer | Propranolol | Propranolol’s solubility has been improved | [170] | ||
Silica | Cur-fls & Cur-sls | Curcumin | Improved solubility with enhanced oral bioavailability up to 7-fold high than convectional suspensions. | [171] | |
Thin film hydration sonication | Glycol, Eudragit S100 | Sorafenib | It improved systemic exposure of about four-fold. | [172] | |
Thin-film hydration sonication | Lecithin | Cefotaxime | About five-fold increase of in oral bioavailability and improved solubility | [173] | |
Thin-film hydration sonication | Soy lecithin | Capsaicin | Oral bioavailability and improved solubility increase about three-fold. | [174] | |
Film deposition on the carrier | HSPC | Lopinavir | Improved solubility with enhanced oral bioavailability up to 2-fold. | [175] | |
Thin-film hydration sonicate | DSPC | Asinine maleate | About one-fold increase in oral bioavailability and improved solubility | [176] | |
Thin-film hydration sonication-freeze thawing | SPC | Spironolactone | Enhanced oral bioavailability with improved solubility up to 2-fold. | [177] | |
High-pressure homogenization | Poly Na styrene sulfonate | Paclitaxel | About 14 -fold increase in oral bioavailability and improved solubility and drug dissolution: 20% (120 min). | [178] | |
Antisolvent precipitation | Pluronic® F68 | Puerarin | Enhanced oral bioavailability with improved solubility up to 4-fold | [179] | |
Spray drying | SDS | Alisertib isoproxil | Drug dissolution: ~14% (1/2 min) enhanced oral bioavailability with improved solubility up to 4-fold. | [180] | |
Antisolvent precipitation | Ethyl cellulose | Domperidone | Fifty percent (30 min) and 65 percent (60 min) drug dissolution and enhanced oral bioavailability with improved solubility up to 2-fold. | [181] | |
Precipitation-sonication | PVA | Cinnarizine | One hundred percent drug in dissolution (240 s) enhanced oral bioavailability with improved solubility up to 2-fold. | [182] | |
Magnetic stirring-milling | PVP-K30 | Glyburide | 100 percent drug in dissolution (30 min) increased oral bioavailability with improved solubility up to four-fold. | [183] | |
Hot homogenization sonication | Stearic acid | Rosuvastatin | Drug release: ~45 percent (120 min) and ~80 percent (10 h) Improved oral bioavailability with improved solubility up to 8-fold. | [184] | |
Micro emulsification | Compritol | Rifampicin | Enhanced oral bioavailability with increased solubility up to 8-fold. | [185] | |
Emulsification sonication | Precirol® ATO-5, palmitic acid, Gelucire® 50/13, N | Resveratrol | Enhanced oral bioavailability and having a higher level of solubility up to 7-fold. | [186] |